Results 131 to 140 of about 408,394 (320)

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Co‐Creation in Research: Further Reflections From the ‘Co‐Creating Safe Spaces’ Project

open access: yesHealth Expectations
Background Applied research using co‐creation methods is rarely described or evaluated in detail. Practical evidence of co‐creation processes and collaboration effectiveness is needed to better understand its complex and dynamic nature.
Scott J. Fitzpatrick   +17 more
doaj   +1 more source

CONEC Volunteer Matching with Legal Service Providers [PDF]

open access: yes, 2013
In early 2013, with Comprehensive Immigration Reform (CIR) looming on the horizon, Silicon Valley Community Foundation launched a technology innovation project to support the technology needs and aspirations of immigration legal services providers in San

core  

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira   +14 more
wiley   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

open access: yesMolecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian   +10 more
wiley   +1 more source

Co-creation

open access: yes, 2022
Pinchbeck, Michael, Baynton, Rachel
openaire   +2 more sources

How collaborative innovation and co-creation can deliver value: a stakeholder approach [PDF]

open access: yes
This project explores how collaborative innovation and co-creation between stakeholders can deliver value for firms. In today’s increasingly competitive and fast-changing global marketplace, firms must seek to develop more frequent and higher quality ...
Clark, Moira   +2 more
core  

Open collaboration strategy of international retailers: an analysis of co-creator [PDF]

open access: yes, 2017
Nowadays, online channels provide better distribution and communication strategies between companies and consumers. The importance of establishing online tools based on innovations and customer participation, is equally applicable to the international ...
Alarcón del Amo, María del Carmen   +4 more
core  

Home - About - Disclaimer - Privacy